Sonelokimab (ALX 0761, M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research.
Purity:
>99.0%
CAS Number:
[1414386-05-2]
Target:
IL Receptor/Related
* VAT and and shipping costs not included. Errors and price changes excepted